The Metabotropic Glutamate 5 Receptor Modulates Extinction and Reinstatement of Methamphetamine-Seeking in Mice

Methamphetamine (METH) addiction is characterized by profound changes in brain glutamate systems, yet there are currently no effective medications for treating the condition. The metabotropic glutamate 5 receptor (mGlu5) has been identified as a key player in the addictive properties of substances like cocaine and alcohol, leading researchers to examine its specific role in METH-seeking. This study sought to determine whether mGlu5 is necessary for METH-related behaviors, including drug consumption, place preference, extinction, and reinstatement of drug-seeking, by comparing mGlu5 knockout (KO) mice to wild-type littermates.

Researchers subjected mGlu5 KO and wild-type mice to a battery of behavioral paradigms, including conditioned place preference (CPP) and intravenous self-administration (IVSA). To ensure results were specific to the drug rather than a general learning deficit, the team also tested the mice using sucrose as a natural reward. The core of the study focused on whether the absence of the mGlu5 receptor affected the mice's ability to extinguish their operant response to METH and whether they were more prone to relapsing when presented with cues previously associated with the drug.

The study revealed a striking dissociation between METH consumption and METH seeking. The mGlu5 KO mice acquired and maintained METH self-administration at levels indistinguishable from wild-type mice, indicating that the receptor is not required for the initial reinforcement or motivation to consume the drug. However, the KO mice displayed a significant impairment in extinguishing their behavior: they required more sessions to stop pressing the lever for METH and showed a much higher propensity to reinstate their drug-seeking behavior when cues were reintroduced. Importantly, this phenotype was not observed with sucrose, suggesting that mGlu5 specifically regulates the extinction of drug-associated behaviors and the salience of drug-related environmental cues. These findings suggest that targeting mGlu5 could potentially help in reducing relapse by modulating the cognitive and contextual processing of drug-associated memories.